MET Exon 14 Skipping Mutations in Non–Small Cell Lung Cancer

home / insights / met-exon-14-skipping-mutations-non-small-cell-lung-cancer

MET Exon 14 Skipping Mutations in NSCLC

EP. 1: MET Exon 14 Skipping Mutations in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
March 29th 2021

Drs Joshua M. Bauml and Lyudmila A. Bazhenova describe what is understood regarding the behavior of MET exon 14 skipping mutations in non–small cell lung cancer and remark on their prevalence among specific patient populations.

Advances in Targeting MET Exon 14 Skipping Mutations in NSCLC

EP. 2: Advances in Targeting MET Exon 14 Skipping Mutations in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
March 29th 2021

Drs Joshua M. Bauml and Benjamin Levy react to the development of novel therapies that specifically target MET exon 14 skipping mutations in non–small cell lung cancer.

Testing to Identify MET Exon 14 Mutations in NSCLC 

EP. 3: Testing to Identify MET Exon 14 Mutations in NSCLC 

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 5th 2021

Recommendations for using next-generations sequencing panels as well as liquid biopsies to help identify MET exon 14 skipping mutations and other oncogenic drivers in patients with non–small cell lung cancer.

Capmatinib for MET Exon 14-Mutated NSCLC

EP. 4: Capmatinib for MET Exon 14-Mutated NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 5th 2021

Discussion on the FDA approval of capmatinib, a MET inhibitor, as treatment for patients with MET exon 14-mutated non–small cell lung cancer based on data demonstrated by the GEOMETRY mono-1 study.

Tepotinib for MET Exon 14 Skipping Mutations in NSCLC

EP. 5: Tepotinib for MET Exon 14 Skipping Mutations in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 12th 2021

Implications for treating patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations with tepotinib, a MET inhibitor, based on data revealed by the VISION trial.

CNS Response to MET Inhibition in NSCLC

EP. 6: CNS Response to MET Inhibition in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 12th 2021

The significance of using MET inhibitors to manage patients who have MET exon 14 skipping mutations in non–small cell lung cancer with CNS (central nervous system) involvement.

MET Inhibitors in NSCLC: Treatment Selection

EP. 7: MET Inhibitors in NSCLC: Treatment Selection

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 19th 2021

A comparison between the MET inhibitors available to treat MET exon 14 skipping mutations in non–small cell lung cancer and factors that should be considered when selecting a type 1 or type 2 MET-directed therapy.

MET Inhibitors in NSCLC: Toxicity Management

EP. 8: MET Inhibitors in NSCLC: Toxicity Management

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 19th 2021

Drs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.

MET Inhibitors in NSCLC: Mechanisms of Resistance

EP. 9: MET Inhibitors in NSCLC: Mechanisms of Resistance

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 26th 2021

The rationale for using MET inhibitors as first-line therapy for patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations and considerations for sequencing later lines of therapy based on what is known to date about mechanisms of resistance to MET inhibitors.

Current and Future Use of MET Inhibitors in NSCLC

EP. 10: Current and Future Use of MET Inhibitors in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 26th 2021

Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.